Changes in Thymus and Activation-Regulated Chemokine in Patients With Type 2 Inflammatory Disease Receiving Dupilumab

Zhou, B; Liang, S; Shang, S; Xiang, L; Li, L

Zhou, B; Liang, S; Shang, S; Xiang, L; Li, L.

Affiliation

Zhou, B; Capital Medical University. Beijing Friendship Hospital. Department of Dermatology. Beijing. China
Liang, S; Capital Medical University. Beijing Friendship Hospital. Department of Dermatology. Beijing. China
Shang, S; Capital Medical University. Beijing Friendship Hospital. Department of Dermatology. Beijing. China
Xiang, L; Capital Medical University. Beijing Friendship Hospital. Department of Dermatology. Beijing. China
Li, L; Capital Medical University. Beijing Friendship Hospital. Department of Dermatology. Beijing. China

J. investig. allergol. clin. immunol ; 33(1): 74-75, 2023.

Article in En | IBECS | ID: ibc-216415

Responsible library: ES1.1

Localization: ES15.1 - BNCS

Subject(s)

Humans; Dermatitis, Atopic/drug therapy; Antibodies, Monoclonal, Humanized; Thymus Gland; Cytokines; Inflammation/drug therapy; Severity of Illness Index; Treatment Outcome

Key words

Thymus and activation-regulated chemokine; Type 2 inflammatory disease; Atopic dermatitis. Dupilumab; Citoquina de activación regulada del timo; Enfermedad inflamatoria tipo 2; Dermatitis atópica. Dupilumab

Fulltext

Add to My VHL

XML

Search on Google

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Thymus Gland / Cytokines / Dermatitis, Atopic / Antibodies, Monoclonal, Humanized / Inflammation Limits: Humans Language: En Journal: J. investig. allergol. clin. immunol Year: 2023 Document type: Article

Fulltext

Add to My VHL

XML

Search on Google